$77.5MSeries A, 17 March 2026
Launch financing funds a Phase 2b study of AP306, licensed from Alebund outside Greater China.
- Amount
- $77.5M
- Stage
- Series A
- Announced
- 17 March 2026
- Lead
- Abingworth
- Other investors
- DaVita Venture Group, F-Prime, Curie.Bio, SymBiosis, U.S. Renal Care
- Use of funds
- Launch financing funds a Phase 2b study of AP306, licensed from Alebund outside Greater China.
- Checked
- Announced by the company
- Sources
- R1 Therapeutics launches with $77.5M Series A for kidney disease biospace.com
R1 Therapeutics launches with $77.5M Series A for kidney disease techstartups.com